Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors

Last revised by Yuranga Weerakkody ◉ on 8 Mar 2021

Citation, DOI, disclosures and article data

Citation:

Weerakkody Y, Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. Reference article, Radiopaedia.org (Accessed on 27 May 2023) https://doi.org/10.53347/rID-87567

DOI:

https://doi.org/10.53347/rID-87567

Permalink:

https://radiopaedia.org/articles/87567

rID:

87567

Article created:

8 Mar 2021, Yuranga Weerakkody ◉

Disclosures:

At the time the article was created Yuranga Weerakkody had no recorded disclosures.

View Yuranga Weerakkody's current disclosures

Last revised:

8 Mar 2021, Yuranga Weerakkody ◉

Disclosures:

At the time the article was last revised Yuranga Weerakkody had no recorded disclosures.

View Yuranga Weerakkody's current disclosures

Revisions:

3 times, by 1 contributor - see full revision history and disclosures

Systems:

Breast

Synonyms:

Cyclin-dependent kinase 4 and 6 inhibitors
CDK 4/6 inhibitors
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors
Cyclin-dependent kinase 4/6 inhibitors

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors which often go under the name palbociclib, ribociclib, and abemaciclib are used in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer.

Biology

CDK 4 and CDK 6 are downstream agents in the estrogen signaling pathway which control entry into the cell cycle. This inhibition is thought to prevent tumor cell progression in the cell cycle.